Clinical Trial: NCT02892123
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Jazz Pharmaceuticals |
| Information Provided By: | Jazz Pharmaceuticals |
| Last Update Posted: | 2024-11-27 |
Study Overview
Brief Summary
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
Official Title
Conditions
Intervention / Treatment
- Drug: ZW25 (Zanidatamab)
- Drug: Paclitaxel
- Drug: Capecitabine
- Drug: Vinorelbine
- Drug: Tucatinib
- Drug: Tucatinib
Other Study ID Numbers
- ZWI-ZW25-101
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Jazz Pharmaceuticals |
| Information Provided By: | Jazz Pharmaceuticals |
| Last Update Posted: | 2024-11-27 |
Study Overview
Brief Summary
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).
Official Title
Conditions
Intervention / Treatment
- Drug: ZW25 (Zanidatamab)
- Drug: Paclitaxel
- Drug: Capecitabine
- Drug: Vinorelbine
- Drug: Tucatinib
- Drug: Tucatinib
Other Study ID Numbers
- ZWI-ZW25-101